Table 4. Odds Ratio for a decline in EQ-5D-3L utility score after 2 years of follow-up according to use of β2-MG apheresis column.

	Number of Patients with decreased EQ-5D-3L utility score n (%)	Odds ratio (95% CI)	P
Crude analysis
β2-MG apheresis column	17 (37.8%)	0.69 (0.35 to 1.36)	0.281
No β2-MG apheresis column	69 (46.9%)	Reference
Multivariable analysis (Model 1)
β2-MG apheresis column	17 (37.8%)	0.61 (0.27 to 1.4)	0.247
No β2-MG apheresis column	69 (46.9%)	Reference
Multivariable analysis (Model 2)
β2-MG apheresis column	17 (37.8%)	0.61 (0.27 to 1.4)	0.247
No β2-MG apheresis column	69 (46.9%)	Reference
Multivariable analysis (Model 3)
β2-MG apheresis column	17 (37.8%)	0.61 (0.28 to 1.31)	0.204
No β2-MG apheresis column	69 (46.9%)	Reference

Model 1: Adjusted for age, age at hemodialysis onset, sex, diabetic nephropathy, dialysis vintage, history of myocardial infarction, ischemic stroke, intracerebral hemorrhage or amputation, predialysis body mass index, Kt/V, geriatric nutritional risk index, hemoglobin, C-reactive protein, use of benzodiazepine agents.

Model 2: Adjusted for covariates in Model 1 plus new-onset myocardial infarction, ischemic stroke, intracerebral hemorrhage or amputation during follow-up.

Model 3: Adjusted for all factors in Model 2 except for Kt/V and C-reactive protein.

Abbreviations: β2-MG, β2-microglobulin; CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels Questionnaire.